See more : Almogim Holdings Ltd (ALMA.TA) Income Statement Analysis – Financial Results
Complete financial analysis of Unity Biotechnology, Inc. (0YC0.L) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Unity Biotechnology, Inc., a leading company in the Medical – Pharmaceuticals industry within the Healthcare sector.
- JSR Corporation (4185.T) Income Statement Analysis – Financial Results
- EnPro Industries, Inc. (NPO) Income Statement Analysis – Financial Results
- Shuangliang Eco-Energy Systems Co.,Ltd (600481.SS) Income Statement Analysis – Financial Results
- STIF Société anonyme (ALSTI.PA) Income Statement Analysis – Financial Results
- Taseko Mines Limited (TKO.L) Income Statement Analysis – Financial Results
Unity Biotechnology, Inc. (0YC0.L)
About Unity Biotechnology, Inc.
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 236.00K | 4.78M | 0.00 | 0.00 | 0.00 | 1.38M | 0.00 |
| Cost of Revenue | 19.70M | 2.18M | 2.88M | 3.45M | 2.66M | 2.18M | 37.37M | 153.00K |
| Gross Profit | -19.70M | -1.94M | 1.90M | -3.45M | -2.66M | -2.18M | -35.99M | -153.00K |
| Gross Profit Ratio | 0.00% | -823.73% | 39.80% | 0.00% | 0.00% | 0.00% | -2,604.27% | 0.00% |
| Research & Development | 20.80M | 36.86M | 38.39M | 67.31M | 70.96M | 58.91M | 37.37M | 13.71M |
| General & Administrative | 18.77M | 20.95M | 23.06M | 24.03M | 20.05M | 16.02M | 9.62M | 5.14M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 18.77M | 20.95M | 23.06M | 24.03M | 20.05M | 16.02M | 9.62M | 5.14M |
| Other Expenses | -14.60M | -17.00K | -983.00K | 182.00K | 4.19M | -245.00K | -103.00K | 0.00 |
| Operating Expenses | 24.97M | 57.81M | 61.45M | 91.33M | 91.00M | 74.92M | 46.99M | 18.84M |
| Cost & Expenses | 44.67M | 57.81M | 61.45M | 91.33M | 91.00M | 74.92M | 46.99M | 18.84M |
| Interest Income | 422.00K | 1.22M | 100.00K | 1.20M | 3.29M | 3.31M | 1.06M | 0.00 |
| Interest Expense | 0.00 | 3.56M | 3.18M | 1.29M | 0.00 | 3.31M | 0.00 | 0.00 |
| Depreciation & Amortization | 1.18M | 2.18M | 2.88M | 3.45M | 2.66M | 2.18M | 1.30M | 153.00K |
| EBITDA | -37.28M | -38.73M | -54.67M | -89.10M | -89.65M | -74.22M | -44.30M | -28.07M |
| EBITDA Ratio | 0.00% | -23,885.17% | -1,202.93% | 0.00% | 0.00% | 0.00% | -3,205.79% | 0.00% |
| Operating Income | -44.67M | -57.57M | -56.67M | -93.93M | -89.65M | -79.47M | -45.61M | -18.84M |
| Operating Income Ratio | 0.00% | -24,394.92% | -1,184.47% | 0.00% | 0.00% | 0.00% | -3,300.14% | 0.00% |
| Total Other Income/Expenses | 4.81M | 13.10M | -4.06M | 86.00K | 7.47M | 3.07M | 952.00K | -11.56M |
| Income Before Tax | -39.86M | -59.93M | -60.73M | -93.84M | -82.18M | -76.40M | -44.66M | -30.40M |
| Income Before Tax Ratio | 0.00% | -25,392.80% | -1,269.34% | 0.00% | 0.00% | 0.00% | -3,231.26% | 0.00% |
| Income Tax Expense | 0.00 | -2.18M | -686.00K | -1.98M | -7.30M | 3.07M | -1.06M | 11.56M |
| Net Income | -39.86M | -57.75M | -60.04M | -91.87M | -74.87M | -76.40M | -44.66M | -30.40M |
| Net Income Ratio | 0.00% | -24,469.07% | -1,255.00% | 0.00% | 0.00% | 0.00% | -3,231.26% | 0.00% |
| EPS | -2.70 | -6.08 | -10.76 | -18.06 | -17.16 | -27.02 | -129.91 | -88.45 |
| EPS Diluted | -2.70 | -6.08 | -10.76 | -18.06 | -17.16 | -27.02 | -129.91 | -88.45 |
| Weighted Avg Shares Out | 14.77M | 9.49M | 5.58M | 5.09M | 4.36M | 2.83M | 343.73K | 343.73K |
| Weighted Avg Shares Out (Dil) | 14.77M | 9.49M | 5.58M | 5.09M | 4.36M | 2.83M | 343.73K | 343.73K |
Source: https://incomestatements.info
Category: Stock Reports